<DOC>
	<DOC>NCT01094678</DOC>
	<brief_summary>The Zilver PTX Registry Study is a prospective, non-randomized, open-label, multicenter single-arm study enrolling patients in Europe, Asia, and North America with de novo or restenotic (including in-stent restenosis) lesions of the above-the-knee femoropopliteal artery (SFA). The primary endpoint of the study is event-free survival (EFS) at 6 months.</brief_summary>
	<brief_title>Zilver® PTX™ Global Registry</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>stenosis of the abovetheknee femoropopliteal artery appropriate size and location of the lesion pregnant or breast feeding failure or inability to give informed consent simultaneously participating in another drug or device study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Peripheral Aterial Disease (PAD)</keyword>
	<keyword>Peripheral Vascular Disease</keyword>
	<keyword>Drug-Eluting Stent</keyword>
	<keyword>Drug-Coated Stent</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
</DOC>